Literature DB >> 12606463

Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability.

R Gómez1, C Simón, J Remohí, A Pellicer.   

Abstract

Convincing evidence supports the role of ovarian-origin vascular endothelial growth factor (VEGF) in inducing vascular permeability (VP) and ascites associated with ovarian hyperstimulation syndrome (OHSS) in mammals, including humans. A circulatory dysfunction has been described in every woman treated with gonadotropins for in vitro fertilization. It is not known, however, whether the action of gonadotropins also includes up-regulation of the VEGF receptor-2 (VEGFR-2) and whether increased VP is also found when milder stimulation is used. Thus, we applied an OHSS animal model to answer these questions. Immature female rats were stimulated with saline (control group) or with high (10 IU of eCG x 4 days + 30 IU hCG, OHSS group) or mild (10 IU of eCG + 10 IU of hCG, mild-stimulation group) doses of gonadotropins. The VP and the expression of whole-VEGF and VEGFR-2 mRNAs were analyzed through time-course experiments (0, 24, 48, and 96 h after hCG). Although eCG increased VP and the expression of VEGF and VEGFR-2 mRNAs in the ovaries of both mild- and OHSS-stimulated animals, hCG further augmented these parameters and produced the highest values after 48 h. A linear correlation was found between increased expression of VEGF and VEGFR-2 mRNAs and enhanced VP in both mild and OHSS groups. Immunohistochemistry showed the presence of VEGF and VEGFR-2 in the granulosa-lutein and endothelial cells of the entire corpus luteum. These studies confirm that in hyperstimulated animals as well as in mildly treated rats, VEGF and VEGFR-2 are overexpressed and associated with an increase in VP, which may be responsible for the accumulation of ascitic fluid in the syndrome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606463     DOI: 10.1095/biolreprod.102.010801

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  18 in total

1.  Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study.

Authors:  Aalie Torabizadeh; Fatemeh Vahidroodsari; Zakieh Ghorbanpour
Journal:  Iran J Reprod Med       Date:  2013-10

Review 2.  Ovarian hyperstimulation syndrome: pathophysiology and prevention.

Authors:  Carolina O Nastri; Rui A Ferriani; Isa A Rocha; Wellington P Martins
Journal:  J Assist Reprod Genet       Date:  2010-02-06       Impact factor: 3.412

3.  Rare genetic variants potentially involved in ovarian hyperstimulation syndrome.

Authors:  Katrien Stouffs; Sari Daelemans; Samuel Santos-Ribeiro; Sara Seneca; Alexander Gheldof; Ali Sami Gürbüz; Michel De Vos; Herman Tournaye; Christophe Blockeel
Journal:  J Assist Reprod Genet       Date:  2018-11-27       Impact factor: 3.412

4.  A unique human chorionic gonadotropin antagonist suppresses ovarian hyperstimulation syndrome in rats.

Authors:  Pratibhasri A Vardhana; Martin A Julius; Susan V Pollak; Evan G Lustbader; Rhonda K Trousdale; Joyce W Lustbader
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

Review 5.  The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome.

Authors:  Lisa C Grossman; Konstantinos G Michalakis; Hyacinth Browne; Mark D Payson; James H Segars
Journal:  Fertil Steril       Date:  2010-09       Impact factor: 7.329

6.  The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Cristiano Busso; Manuel Fernández-Sánchez; Juan Antonio García-Velasco; José Landeras; Augustín Ballesteros; Elkin Muñoz; Sandra González; Carlos Simón; Joan-Carles Arce; Antonio Pellicer
Journal:  Hum Reprod       Date:  2010-02-06       Impact factor: 6.918

7.  The superovulated environment, independent of embryo vitrification, results in low birthweight in a mouse model.

Authors:  Rachel Weinerman; Teri Ord; Marisa S Bartolomei; Christos Coutifaris; Monica Mainigi
Journal:  Biol Reprod       Date:  2017-07-01       Impact factor: 4.285

8.  Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone.

Authors:  Hena Alam; Jennifer Weck; Evelyn Maizels; Youngkyu Park; Eun Jig Lee; Margaret Ashcroft; Mary Hunzicker-Dunn
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

9.  GnRH analogues in the prevention of ovarian hyperstimulation syndrome.

Authors:  Pilar Alama; Jose Bellver; Carmen Vidal; Juan Giles
Journal:  Int J Endocrinol Metab       Date:  2013-04-01

10.  Co action of CFTR and AQP1 increases permeability of peritoneal epithelial cells on estrogen-induced ovarian hyper stimulation syndrome.

Authors:  Pei-Yin Jin; Yong-Chao Lu; Ling Li; Qin-Fu Han
Journal:  BMC Cell Biol       Date:  2012-08-28       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.